Study of Escitalopram in the Treatment of Specific Phobia

Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00121069

Enrollment

Registered

2005-07-21

Start date

2002-09-30

Completion date

2004-09-30

Last updated

2005-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phobic Disorders

Keywords

specific phobia, anxiety, SSRI, clinical trial, escitalopram

Brief summary

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

Detailed description

This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.

Interventions

DRUGEscitalopram

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Adults 18-65 years of age * DSM-IV criteria for specific phobia according to the MINI * For women of childbearing potential, a negative serum pregnancy test at screening * Written informed consent

Exclusion criteria

* Any current primary DSM-IV diagnosis other than specific phobia * History of DSM-IV substance abuse or dependence within the last months * Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition * Suicide risk or serious suicide attempt within the last year * Clinically significant laboratory or EKG abnormality or unstable medical condition * For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study * Subjects needing concurrent use of psychotropic medications

Design outcomes

Primary

Measure	Time frame
Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline	—

Secondary

Measure	Time frame
Response based on CGI-I category	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026